Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01137955 · ClinicalTrials.gov registry record · NA
Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease
A NA study, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT01137955 is a NA study that has completed, run by Columbia University. The registered enrollment target is 50 participants.
The verdict
NCT01137955, a NA study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
Celiac disease is a condition in which the small intestine is damaged by gluten, the storage protein of wheat and similar proteins in barley and rye. The disease can cause different symptoms such as diarrhea, bloating, abdominal pain and weight loss. The majority of patients respond to a gluten-free diet. However some patients (5-30%) have persistent symptoms and are considered to be poor responders to the diet. Bacterial overgrowth in the small intestine accounts for some of the refractory patients. This study seeks to determine if antibiotic therapy with rifaximin relieves the symptoms of patients who are poorly responsive to a gluten-free diet and whether this impacts their breath test results.
Interventions
- DRUG Placebo
- DRUG Rifaximin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01137955
The ClinicalTrials.gov registry entry for NCT01137955 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01137955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01137955 about?
NCT01137955 is a clinical study titled "Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease". Celiac disease is a condition in which the small intestine is damaged by gluten, the storage protein of wheat and similar proteins in barley and rye. The disease can cause different symptoms such as diarrhea, bloating, abdominal pain and weight loss. The majority of patients respond to a gluten-free...
What is the current status of trial NCT01137955?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2006-10. Estimated completion is 2008-04.
What interventions are being tested in trial NCT01137955?
The interventions under investigation include: Placebo (DRUG), Rifaximin (DRUG).
Who is sponsoring clinical trial NCT01137955?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.